Hepatitis D - Pipeline Review, H2 2018

Date: October 16, 2018
Pages: 69
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H0ABAED0AA1EN
Leaflet:

Download PDF Leaflet

Hepatitis D - Pipeline Review, H2 2018
Hepatitis D - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Hepatitis D - Overview
Hepatitis D - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis D - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis D - Companies Involved in Therapeutics Development
CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Globeimmune Inc
Merck & Co Inc
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Hepatitis D - Drug Profiles
Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-18000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myrcludex-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon lambda-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REP-2165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vanitaracin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis D - Dormant Projects
Hepatitis D - Product Development Milestones
Featured News & Press Releases
Sep 24, 2018: Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
Aug 06, 2018: Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Jul 31, 2018: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection
Jul 30, 2018: SomaGenics Awarded Multi-Year Funding for Hepatitis Delta Virus Therapeutic Program
Jun 11, 2018: Replicor Updates Mechanistic and Clinical Data Demonstrating High Rates of Functional Control of HBV and HDV Infection at the Science of HBV Cure 2018
Jun 04, 2018: Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018
Apr 17, 2018: Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018
Apr 13, 2018: Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018
Apr 03, 2018: Replicor to Disclose Updated Data Demonstrating Functional Remission of HBV and HDV at the EASL International Liver Conference 2018
Apr 02, 2018: Eiger BioPharmaceuticals to Participate in Conferences in April
Mar 27, 2018: MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting
Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
Mar 12, 2018: MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta
Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting
Feb 22, 2018: MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hepatitis D, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hepatitis D - Pipeline by CN Bio Innovations Ltd, H2 2018
Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H2 2018
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Hepatitis D - Pipeline by Globeimmune Inc, H2 2018
Hepatitis D - Pipeline by Merck & Co Inc, H2 2018
Hepatitis D - Pipeline by Replicor Inc, H2 2018
Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2018
Hepatitis D - Pipeline by SomaGenics Inc, H2 2018
Hepatitis D - Dormant Projects, H2 2018

LIST OF FIGURES

Number of Products under Development for Hepatitis D, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Globeimmune Inc
Merck & Co Inc
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Skip to top


Hepatitis A - Pipeline Review, H1 2018 US$ 2,000.00 Apr, 2018 · 26 pages

Ask Your Question

Hepatitis D - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: